EFDID: 523269EFD: View Filing

Issuer: Summit Therapeutics Inc. (0001599298) - D

Accession: 0000950123-24-006261 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001599298
  • Entity Name:
    Summit Therapeutics Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2020)
  • Address:
    601 Brickell Key Drive
    Suite 1000
    Miami, FL 33131
  • Persons:
    Related Persons 9
    Robert Duggan
    Executive Officer, Director
    Mahkam Zanganeh
    Executive Officer, Director
    Manmeet Soni
    Executive Officer, Director
    Kenneth Clark
    Director
    Robert Booth
    Director
    Ujwala Mahatme
    Director 
    Ms. Ujwala resigned as a director effective June 12, 2024
    Alessandra Cesano
    Director
    Yu Xia
    Director
    Mostafa Ronaghi
    Director
EDGAR: Offering Information
  • Accession Date:
    06/18/2024
  • First Sale Date:
    06/03/2024
  • Offering Amount:
    $199,999,998
  • Amount Sold:
    $199,999,998
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:NY
EDGAR: Sales Compensation Recipient Information

There were no Sales Compensation Recipient Information associated with this Accession Number.

EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Summit Therapeutics Inc./s/ Manmeet SoniManmeet SoniChief Financial Officer2024-06-18